Plasmacytic ascites is an infrequent complication of multiple myeloma. To date, only few cases have been reported with a very rapidly fatal course unresponsive to therapy. We describe a patient with plasmacytic ascites and quiescent multiple myeloma of 8 years of duration. Disease progression became apparent due to myelomatous ascites, unexplained fever, pancytopenia and bone marrow infiltration. This case showed a complete and long-lasting response after VAD chemotherapy followed by autologous PBSC transplantation. Ascites in association with MM may respond for lengthy periods to high-dose chemotherapy and ASCT. Keywords: multiple myeloma; myelomatous ascites; stem cell transplantation Ascites is a rare complication of multiple myeloma and also an occasional presenting feature of relapse. To date, very few cases have been reported, nearly all with very poor response to standard therapy and a fatal outcome due to progressive myeloma. Ascites occur either at presentation [1] [2] [3] or more often during the disease course.
Ascites is a rare complication of multiple myeloma and also an occasional presenting feature of relapse. To date, very few cases have been reported, nearly all with very poor response to standard therapy and a fatal outcome due to progressive myeloma. Ascites occur either at presentation [1] [2] [3] or more often during the disease course. [4] [5] [6] [7] [8] An IgA 7 and IgG 2-5 predominance has been reported, and less frequently IgD 6 type. We report a further case of plasmacytic ascites in a patient with quiescent multiple myeloma, present for 8 years. The ascites was the presenting feature of denoting progression and we achieved a complete and long-lasting response after VAD chemotherapy followed by autologous PBSC transplantation. To our knowledge there have been no previous reports of the successful use of autologous PBSCT to treat this rare extramedullary complication of plasma cell neoplasia.
Case report
A 51-year-old female was diagnosed with stage IA IgG-K multiple myeloma in 1989. No unfavorable prognostic Correspondence: Dr A Alegre, Hematology Department, Hospital Universitario de la Princesa, C/Diego de Leon, 62 28006 Madrid, Spain Received 4 December 1998; accepted 11 March 1999 markers such as a high level of serum B 2 -microglobulin were observed at diagnosis. She was treated with 12 cycles of intermittent oral melphalan and prednisone at standard doses: melphalan 0.25 mg/kg/day ϫ 4 days and prednisone 60 mg/m 2 /day ϫ 4 days, every 6 weeks. The decision to start chemotherapy was based on the highly undifferentiated plasma cell bone marrow infiltration at diagnosis. After induction treatment, she achieved a stable partial response according to standard criteria 9 and hematopoietic progenitors were mobilized with high-dose cyclophosphamide, 4 g/m 2 i.v., followed by GM-CSF (Leucomax, Molgramostim, Schering-Plough Sandoz, Basel, Switzerland), 8 g/kg s.c. Leukaphereses were carried out on 2 consecutive days during recovery from aplasia, when the white blood cell count was Ͼ1 ϫ 10 9 /l, and 2 ϫ 10 6 /kg CD34 ϩ cells were collected and cryopreserved following standard methods. No purging was performed. After PBSC collection autologous peripheral blood transplantation was postponed due to the stability of the disease.
The patient remained asymptomatic with a minimum serum monoclonal component without progression for 8 years.
In November 1997, she was admitted to our institution after a 3-week history of fever without apparent infective origin, anorexia, weight loss, night sweats and increase of abdominal girth. Physical examination showed cutaneous pallor without jaundice, moderate ascites and mild leg edema. No lymphadenopathy or plasmacytomas were observed. Blood examination revealed pancytopenia (Hb 8 g/dl, WBC 0.7 ϫ 10 9 /l with 61% segmented neutrophils, 37% lymphocytes and 4% monocytes and a platelet count of 30 ϫ 10 9 /l). Serum sodium, potassium, calcium, BUN and creatinine levels were normal. Serum B 2 -microglobulin was 9.1 mg/dl (normal Ͻ3.5), C-reactive protein 4.64 mg/dl (normal Ͻ0.8) and LDH was 1255 IU/l (normal Ͻ400). The patient showed liver dysfunction with AST 209 IU/l (normal Ͻ32), ALT 56 IU/l (normal Ͻ31), GGT 54 IU/l (normal Ͻ45) and alkaline phosphatase 472 IU/l (normal Ͻ279). Serum electrophoresis showed a monoclonal peak in the gamma region of 2.2 g/dl, with 5.6 g/dl total protein and 2 g/dl albumin. Bence-Jones protein was not present and a skeletal survey revealed no osteolytic lesions or osteopenia. Bone marrow aspirate and biopsy showed a 35% infiltration of atypical undifferentiated plasma cells with pleomorphism, prominent nucleoli and abundant blue cytoplasm. Abdominal ultrasound revealed moderate ascitic /kg CD34 ϩ cells, engraftment was rapid and complete. Currently, the patient is in complete remission according to standard criteria 9 with no evidence of multiple myeloma 14 months from her relapse. She remains on maintenance therapy with low dose of s.c. ␣-2b interferon.
Discussion
The common factor with malignant plasmacytic ascites appears to be peritoneal implantation with tumor. Liver involvement was minimal or absent in the majority of cases.
2,4 Development of extraosseous lesions other than peritoneal deposits during the course of the disease have been frequently described. 4 In most cases, as in the present case, the plasma cells in the ascitic fluid have shown a highly atypical histologic appearance, with numerous large, bizarre and immature cells, and lack of cohesion among them. 4, 5, 8 The diagnosis of cavity involvement was made by cytologic examination of air-dried smears of ascitic fluid, and was confirmed by the immunocytochemical demonstration of monoclonality of the plasma cells.
This extramedullary complication of MM is usually unresponsive to conventional therapy (chemotherapy and/or radiotherapy) and is rapidly fatal, with a median survival of 1.5-2 months from the development of the ascites. [1] [2] [3] [4] [5] Most patients have died within 6 months due to dissemination of the myelomatous process, and only two reported cases have survived for more than 12 months. 2, 3 Plasmacytic ascites may reflect a large tumor mass or be the manifestation of the terminal, aggressive phase of myeloma, resulting from evolution to a more undifferentiated, aggressive clone of plasma cells. 4, 5 Although encouraging results with high-dose therapy followed by ASCT have been reported in MM, 10 to our knowledge this is the first reported case of myelomatous ascites with a favorable outcome achieved with this strategy. In conclusion, the present case shows that ascites in the course of MM may respond for protracted periods to high-dose chemotherapy and ASCT.
